CD34 and myeloproliferative disorder: We also confirmed upregulation of these top ten common DEGs in engineered CALR MUT HSPCs via RT-qPCR (Supplementary Fig. 4C) and in MPN-patient-derived CD34+ HSPCs (Supplementary Table 1) compared to healthy controls, with more pronounced effects seen in DEL than INS samples (Fig. 4E).